License: Creative Commons Attribution 4.0 PDF - Published Version (3MB) |
- URN to cite this document:
- urn:nbn:de:bvb:355-epub-541462
- DOI to cite this document:
- 10.5283/epub.54146
Abstract
Abstract Background: The outcome for patients with high-risk neuroblastoma remains poor and novel treatment strategies are urgently needed. The RIST protocol represents a novel metronomic and multimodal treatment strategy for high-risk neuroblastoma combining molecular-targeted drugs as ‘pre-treatment’ with a conventional chemotherapy backbone, currently evaluated in a phase II clinical trial. ...
Owner only: item control page